General Information of Drug (ID: DM4ZLTY)

Drug Name
ABBV-2222 Drug Info
Synonyms QVDYQHXNAQHIKH-YMBRHYMPSA-N; ABBV 2222; 1918143-53-9; BCP25130
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Phase 2 [1]
Cross-matching ID
PubChem CID
121301049
CAS Number
CAS 1918143-53-9
TTD Drug ID
DM4ZLTY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [2]
Crofelemer DM4AMQZ HIV-associated diarrhoea 1A2Z Approved [3]
Tezacaftor and ivacaftor DMY62FC Acute lung injury NB32.3 Approved [4]
VX-661 DMJBXO3 Cystic fibrosis CA25 Phase 3 [5]
GLPG-1837 DMOCRYB Cystic fibrosis CA25 Phase 2 [1]
iOWH032 DM5TMYC Diarrhea ME05.1 Phase 2 [6]
Lumacaftor DMCLWDJ Cystic fibrosis CA25 Phase 2 [7]
QBW251 DMQ5APT Chronic obstructive pulmonary disease CA22 Phase 2 [8]
ABBV-3067 DMB01L5 Cystic fibrosis CA25 Phase 1 [1]
ABBV-2737 DMU6K37 Cystic fibrosis CA25 Phase 1 [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
cAMP-dependent chloride channel (CFTR) TTRLZHP CFTR_HUMAN Modulator [1]

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
6 Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
7 A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
8 Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.